- Home
- HSII vs IOVA Comparison
HSII vs IOVA Comparison
Compare HSII & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- IOVA
- Stock Information
- Founded
- HSII 1953
- IOVA 2007
- Country
- HSII United States
- IOVA United States
- Employees
- HSII N/A
- IOVA N/A
- Industry
- HSII Diversified Commercial Services
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSII Consumer Discretionary
- IOVA Health Care
- Exchange
- HSII Nasdaq
- IOVA Nasdaq
- Market Cap
- HSII 904.6M
- IOVA 771.4M
- IPO Year
- HSII 1999
- IOVA N/A
- Fundamental
- Price
- HSII $46.30
- IOVA $3.13
- Analyst Decision
- HSII Buy
- IOVA Buy
- Analyst Count
- HSII 2
- IOVA 10
- Target Price
- HSII $49.00
- IOVA $12.22
- AVG Volume (30 Days)
- HSII 122.7K
- IOVA 23.7M
- Earning Date
- HSII 08-04-2025
- IOVA 08-07-2025
- Dividend Yield
- HSII 1.30%
- IOVA N/A
- EPS Growth
- HSII N/A
- IOVA N/A
- EPS
- HSII 0.37
- IOVA N/A
- Revenue
- HSII $1,116,954,000.00
- IOVA $212,679,000.00
- Revenue This Year
- HSII $6.41
- IOVA $86.62
- Revenue Next Year
- HSII $2.65
- IOVA $69.95
- P/E Ratio
- HSII $126.09
- IOVA N/A
- Revenue Growth
- HSII 6.10
- IOVA 11070.12
- 52 Week Low
- HSII $34.67
- IOVA $1.64
- 52 Week High
- HSII $49.02
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- HSII 53.19
- IOVA 62.71
- Support Level
- HSII $45.31
- IOVA $1.70
- Resistance Level
- HSII $47.30
- IOVA $4.33
- Average True Range (ATR)
- HSII 1.08
- IOVA 0.35
- MACD
- HSII -0.21
- IOVA 0.17
- Stochastic Oscillator
- HSII 26.68
- IOVA 54.55
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.